Apaf-1 Blocking Peptide

Confirm delete?

Cat No: 360780

Antibodies - Blocking Peptides

Each vial contains 200 µg of lyophilized peptide corresponding to amino acids 12 to 28 of human Apaf-1.{6894} Apoptosis is related to many diseases and is induced by a family of cell death receptors and their ligands. Cell death signals are transduced...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

peptides controls apoptosis cell death caspases CED-4 Apaf2 Apaf3 Apaf-2 Apaf-3 Apafs antibodies Apaf1 CED4 protease-activating factors proteases

Product Overview:
Each vial contains 200 µg of lyophilized peptide corresponding to amino acids 12 to 28 of human Apaf-1.{6894} Apoptosis is related to many diseases and is induced by a family of cell death receptors and their ligands. Cell death signals are transduced by death domain containing adapter molecules and members of the caspase family of proteases. The mammalian homologues of the key cell death gene CED-4 in C. elegans has been identified recently from human and mouse and designated Apaf-1 (for apoptosis protease-activating factor 1).{6894,6873} Apaf-1 binds to cytochrome c (Apaf-2) and caspase-9 (Apaf-3), which leads to caspase-9 activation. Activated caspase-9 in turn cleaves and activates caspase-3, one of the key proteases responsible for the proteolytic cleavage of many key proteins in apoptosis.{6874} Apaf-1 can also associate with caspase-4 and caspase-8.{6878} Apaf-1 is ubiquitously expressed in human tissues.{6894}

Size	200 µg
Shipping	dry ice
Formulation	A lyophilized peptide
Custom Code	3504.00
UNSPSC code	41105329

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.